Sudden Cardiac Death Clinical Trial
Official title:
Post-market Clinical Follow-up Study Evaluating the Efficacy and Safety of LifeVest in Real-life Settings in France
This post-market study is a prospective observational study evaluating the efficacy and safety of the LifeVest in real-life settings.
LifeVest has obtained coverage for 4 indications: (i) implantable cardiac defibrillator (ICD) removal due to cardiac device infections, (ii) a bridge to heart transplantation, (iii) in the early post-myocardial infarction period with left ventricular (LV) dysfunction (LVEF <30%), (iv) and a recent coronary revascularization with LV dysfunction (LVEF < 30%). There is no current comparator to LifeVest. In France, patients at high risk for sudden cardiac arrest (SCD) and waiting for heart transplant or ICD are hospitalized or discharged home without any particular ECG monitoring. LifeVest has been demonstrated to automatically detect and terminate rapid ventricular arrhythmias. Introduction of LifeVest into the current patient management would definitely improve the clinical outcomes and benefit the patients with temporary risk of SCD. The use of LifeVest was shown to be effective in protecting patients against SCD in the United States. However, the clinical impact of using LifeVest in France remains unassessed. Therefore we are planning to conduct a post-market study in France to provide efficacy and safety data for the reimbursement dossier renewal before April 2017. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02923726 -
Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
|
N/A | |
Recruiting |
NCT05175937 -
REal World Assessment for Patients Implanted With Implantable CardioverTer DefibrIllatOr Using Bluetooth Technology
|
||
Completed |
NCT02026102 -
A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)
|
N/A | |
Completed |
NCT01262508 -
Development of Algorithms to Predict Hemodynamic Instability
|
N/A | |
Completed |
NCT00998218 -
Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction
|
Phase 3 | |
Completed |
NCT00845286 -
Marathon, Genetics, Inflammation and the Cardiovascular System: MAGIC-Trial
|
N/A | |
Active, not recruiting |
NCT00562757 -
Prospective Study to Identify Patients at Risk of Dangerous Ventricular Arrhythmias
|
N/A | |
Completed |
NCT00622453 -
Arrhythmias in Myotonic Muscular Dystrophy
|
N/A | |
Completed |
NCT03833843 -
Sudden Cardiac Death in Systemic Right Ventricle
|
||
Completed |
NCT04024865 -
Domperidone and Risk of Serious Cardiac Events in Postpartum Women
|
||
Recruiting |
NCT05799833 -
Low QRS Voltages in Young Healthy Individuals and Athletes
|
||
Recruiting |
NCT05694572 -
Post-market Surveillance of Micorport CRM Cardiac Implantable Electronic Devices
|
||
Not yet recruiting |
NCT03622307 -
Subcutaneous ICD Therapy Combined With VT Ablation for the Secondary Prevention of Sudden Cardiac Death
|
N/A | |
Recruiting |
NCT02056509 -
The Effect of Chest Compression and Ventilation Coordination During Cardiopulmonary Resuscitation.
|
N/A | |
Recruiting |
NCT02058771 -
Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
|
||
Terminated |
NCT01948206 -
Study of Paced QRS Duration as a Marker of Sudden Cardiac Death
|
N/A | |
Completed |
NCT01227785 -
Next Generation INCEPTA Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy (CRT-D) Field Following Study
|
N/A | |
Completed |
NCT00534300 -
Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker
|
Phase 1/Phase 2 | |
Terminated |
NCT00524862 -
Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death
|
N/A | |
Recruiting |
NCT00181233 -
Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk
|